Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CATX

Perspective Therapeutics (CATX)

Perspective Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CATX
DateTimeSourceHeadlineSymbolCompany
24/05/202422:01GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsAMEX:CATXPerspective Therapeutics Inc
20/05/202421:00GlobeNewswire Inc.Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024AMEX:CATXPerspective Therapeutics Inc
15/05/202421:00GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsAMEX:CATXPerspective Therapeutics Inc
03/05/202421:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming May Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
02/05/202421:00GlobeNewswire Inc.Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
30/04/202421:00GlobeNewswire Inc.Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsAMEX:CATXPerspective Therapeutics Inc
08/04/202422:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming April Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
28/03/202422:30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
18/03/202423:00GlobeNewswire Inc.Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaAMEX:CATXPerspective Therapeutics Inc
11/03/202423:00GlobeNewswire Inc.Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024AMEX:CATXPerspective Therapeutics Inc
06/03/202400:00GlobeNewswire Inc.Perspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityAMEX:CATXPerspective Therapeutics Inc
05/03/202401:45GlobeNewswire Inc.Perspective Therapeutics Announces $87.4 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
27/02/202400:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
13/02/202400:00GlobeNewswire Inc.Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceAMEX:CATXPerspective Therapeutics Inc
23/01/202408:05GlobeNewswire Inc.Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
18/01/202423:00GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
18/01/202408:05GlobeNewswire Inc.Perspective Therapeutics Announces Proposed Public OfferingAMEX:CATXPerspective Therapeutics Inc
18/01/202400:00GlobeNewswire Inc.Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01AMEX:CATXPerspective Therapeutics Inc
10/01/202408:10AllPennyStocks.comAnother Healthcare Stock Stealing The ShowAMEX:CATXPerspective Therapeutics Inc
10/01/202400:00GlobeNewswire Inc.Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing CapabilityAMEX:CATXPerspective Therapeutics Inc
10/01/202400:00GlobeNewswire Inc.Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective TherapeuticsAMEX:CATXPerspective Therapeutics Inc
06/01/202400:00GlobeNewswire Inc.Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer TreatmentAMEX:CATXPerspective Therapeutics Inc
03/01/202400:00GlobeNewswire Inc.Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceAMEX:CATXPerspective Therapeutics Inc
13/12/202300:00GlobeNewswire Inc.Perspective Therapeutics Divests Brachytherapy BusinessAMEX:CATXPerspective Therapeutics Inc
08/12/202300:00GlobeNewswire Inc.Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine TumorsAMEX:CATXPerspective Therapeutics Inc
15/06/202306:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
15/06/202306:42Edgar (US Regulatory)Specialized Disclosure Report (sd)AMEX:CATXPerspective Therapeutics Inc
07/06/202306:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
16/05/202307:23Edgar (US Regulatory)Quarterly Report (10-q)AMEX:CATXPerspective Therapeutics Inc
16/05/202307:16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:CATXPerspective Therapeutics Inc
 Showing the most relevant articles for your search:AMEX:CATX

Your Recent History

Delayed Upgrade Clock